clinical trial · NCT05739292
Safety and Immunogenicity of Pentavalent Meningococcal Conjugate Vaccine (EuNmCV-5) in Healthy Adults Aged 19 to 55 Years Old
EuBiologics Co.,Ltd·phase1·completed·n = 60
Infection, MeningococcalEuNmCV-5Menveo
brief summary
Phase I study to evaluate safety and immunogenicity in healthy adult subjects following a single dose administration of Meningococcal (Group A, C, W-135, X, and Y)-CRM197 Conjugate vaccine
started
Feb 28, 2023
primary completion
May 10, 2023
completion
Oct 4, 2023
last updated
Dec 20, 2023
official title
A Single Center, Randomized, Observer-blinded, Active Comparator Phase I Study to Assess the Safety and Immunogenicity of Meningococcal (Groups A, C, W-135, X and Y) Conjugate Vaccine in Healthy Adults Aged 19 to 55 Years Old
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol